A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid Arthritis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
A Phase I, open-label study of CLN-978 in patients with treatment-refractory rheumatoid arthritis.
Epistemonikos ID: 0b727ad48a7fa8434f9a8fb8dc8babc43687cae7
First added on: May 31, 2025